GLP-1 RECEPTOR AGONISTS AND USE THEREOF Russian patent published in 2022 - IPC C07D405/12 C07D405/14 C07D413/14 A61K31/496 A61P3/00 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, where R is F; p is 0 or 1; ring A is phenyl or pyridinyl; m is 0, 1, 2 or 3; each R¹ is independently selected from a group comprising halogen, -CN, -C_1-3alkyl or -OC 1-3 alkyl, where alkyl of C_1-3alkyl and OC_1-3 alkyl is substituted with 0–3 F atoms; R² is H or -C_1-3 alkyl, where said alkyl is substituted with from 0 to 1 OH; XL is N-CH₂ or cyclopropyl; Y is CH or N; R⁴ denotes -C_1-3alkyl, -C_0-3alkylene-C_3-6cycloalkyl, -C_0-3alkylene-R⁵ or -C_1-3alkylene-R⁶, where said alkyl can be substituted, as far as valence allows, 0–3 substitutes independently selected from group comprising 0–3 F atoms, and 0–1 substituent selected from the group consisting of -C_0-1alkylene-OR^O, -SO₂-N(R^N)₂, -C(O)-N(R^N)₂, -N(C=O)(R^N) and -N(R^N)₂; R⁵ is 4–6 membered heterocycloalkyl selected from oxetanyl, tetrahydrofuranyl, morpholinyl, 1,3-oxazolidinyl and pyrrolidinyl, where said heterocycloalkyl can be substituted with 0–2 substitutes, as far as valence allows, independently selected from group comprising 0–1 oxo group (=O); R⁶ denotes 5–6-membered heteroaryl selected from oxazolyl, imidazolyl, pyridinyl, pyrazolyl and triazolyl, where said heteroaryl can be substituted with 0–2 substitutes, as far as valence allows, independently selected from a group comprising: 0–2 -C_1-3alkyl, where alkyl can be substituted with 0–3 substitutes, as far as valence allows, independently selected from group comprising 0–1 -OR^O; each R^O independently denotes H or -C_1-3alkyl, where C_1-3alkyl can be substituted with 0–3 F atoms; each R^N independently denotes H or -C_1-3alkyl; Z¹, Z² and Z³ all denote -CR^Z or one of Z¹, Z² and Z³ denote N and the other two denote -CR^Z; and each R^Z independently denotes H, F, Cl or -CH₃; or 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-{2-[methyl](methylsulfonyl)amino]ethyl}-1H-benzimidazole-6-carboxylic acid or its pharmaceutically acceptable salt. Invention also relates to a pharmaceutical composition having GLP-1R agonist activity, containing a therapeutically effective amount of the compound according to the invention and an inert excipient.

EFFECT: disclosed are 6-carboxy derivatives of benzimidazoles and 4-aza-, 5-aza- and 7-azabenzimidazoles as GLP-1R agonists.

33 cl, 2 dwg, 13 tbl, 102 ex